Memantine hydrochloride

@article{Witt2004MemantineH,
  title={Memantine hydrochloride},
  author={A. Witt and Nancy Macdonald and P. Kirkpatrick},
  journal={Nature Reviews Drug Discovery},
  year={2004},
  volume={3},
  pages={109-110}
}
Memantine hydrochloride (Namenda; Forest/Merz), which acts to protect neurons against toxicity caused by overactivation of N-methyl-D-aspartate receptors, became the first drug to be approved by the US FDA for the treatment of moderate to severe Alzheimer's disease in October 2003, after its approval for the same indication in the European Union in 2002. What influence could this have on its market potential? 
Memantine and Kynurenic Acid: Current Neuropharmacological Aspects
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Therapeutic efficacy of novel memantine nitrate MN‐08 in animal models of Alzheimer’s disease
Mechanisms of NMDA receptor inhibition by memantine and ketamine
...
1
2
3
4
...

References

SHOWING 1-7 OF 7 REFERENCES
NMDA receptor pathways as drug targets
Treatment of Alzheimer's disease.
Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels.
  • J. Bormann
  • Chemistry, Medicine
  • European journal of pharmacology
  • 1989
The adamantyl group in medicinal agents. II. Anabolic steroid 17-beta-adamantoates.